Abstract
Drugs used to treat schizophrenia improve mainly the positive symptoms of the disease, have low tolerability, and high rates of discontinuation of treatment. Recent evidence suggests that the endocannabinoid system may be a new target for the treatment of this disorder. The cannabinoid receptor type 2 (CB2) can modulate dopaminergic neurotransmission and attenuate the effects of proinflam…